Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Hip

Eligibility Criteria

• 1. Patients with indication of Osteoarthritis. Can be from degeneration or chronic injury.
• 2. Patients range from 18-90 years of age.
• 3. Patients must be able to comply with treatment plan, laboratory tests and periodic interviews.
• 4. Patients with adequate renal function, Creatinine ≤ 1.5 mg/dl.
• 5. Patients with adequate cardiac and respiratory function.
• 6. Patients with adequate blood coagulation activity, PT(INR) \< 1.5, APTT
• 7. Patients must have adequate immune system function, with no known immunodeficiency disease.
• 8. Greater than 6 months hip pain with the index side (left or right).
• 1. Neoplastic cancer within 5 years prior to screening, except for cutaneous basal cell or squamous cell cancer resolved by excision
• 2. Presence of clinically significant acute or unstable cardiovascular and cerebrovascular (stroke).
• 3. Diagnosis of a transient ischemic attack in the 6 months prior to screening.
• 4. Patients infected with hepatitis B, C or HIV.
• 5. Patients with Body Mass Index (BMI) \> 40kg/m2
• 6. Presence of active infection.
• 7. Any other illness, psychiatric disorder, alcohol or chemical dependence that in the opinion of the investigator would render a patient unsuitable to participate in the study.
• 8. Conditions/therapies/factors which could confound or interfere with the evaluation of pain/mobility including, but not limited to:
• * Treatments with strong opioid drugs in the previous 4 weeks for other pain rather than hip osteoarthritis
• * Corticosteroid injection at treatment site within 1 month
• * Consistent use of NSAIDs within 48 hours of procedure.